Fennec Pharmaceuticals partners exclusively with Norgine to commercialize Pedmarqsi in Europe, Australia and New Zealand.

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) and Norgine have partnered for an exclusive licensing deal to distribute PEDMARQSI® in Europe, Australia, and New Zealand. PEDMARQSI® is the EU and U.K.’s first approved therapy to prevent hearing loss from cisplatin chemotherapy in young patients with specific tumors. Fennec will receive €40 million upfront, potential milestone payments of up to €210 million, and royalties on sales. Norgine will manage commercial activities and hold marketing authorizations.

LaBarge Weinstein LLP, with a dedicated team led by Randy Taylor is honored to have provided comprehensive legal counsel and support to Fennec Pharmaceuticals.

Read more about this: Fennec Pharmaceuticals partners exclusively with Norgine to commercialize Pedmarqsi in Europe, Australia, and New Zealand.